[1] Armstrong RA. Visual dysfunction in Parkinson's disease[J]. Int Rev Neurobiol, 2017, 134(6):921-946. [2] Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson's disease:a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2017, 390(10103):1664-1675. [3] McDermott KL, Fisher N, Bradford S, et al. Parkinson's disease mild cognitive impairment classifications and neurobehavioral symptoms[J]. Int Psychogeriatr, 2017, 30(2):253-260. [4] 中华医学会神经病学分会帕金森病及运动障碍学组, 中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会. 中国帕金森病的诊断标准(2016版)[J]. 中华神经科杂志, 2016, 49(4):268-271. [5] Wong A, Law LSN, Liu WY, et al. Montreal cognitive assessment[J]. Stroke, 2015, 642(4):342-349. [6] 陈爱春,舒化青,肖瑞,等.帕金森病患者出现认知功能障碍的危险因素logistic回归分析[J].中国实用神经疾病杂志,2016,19(2):82-84. [7] 刘茹, 张素芬, 李红军, 等.PD患者认知功能障碍的危险因素分析[J].河北医科大学学报,2019, 40(10):1211-1213. [8] Majbour N, El-Agnaf O. Cognitive impairment in Parkinson's disease[J]. Lancet Neurol, 2017, 16(1):23-24. [9] Caspell-Garcia C, Simuni T, Tosun-Turgut D, et al. Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease[J]. PLoS One, 2017, 12(5):e0175674. [10] Kliushnik TP, Androsova LV, Mikhaylova NM, et al. Systemic inflammatory markers in age-associated cognitive impairment and Alzheimer’s disease[J]. Zh Nevrol Psikhiatr Im S S Korsakova, 2017, 117(7):74-79. [11] 许利,巩娟瑜,戴萍.帕金森病认知功能障碍的危险因素分析[J].解放军预防医学杂志,2019, 37(7):118-119. [12] 刘晶, 周旭平, 张莉, 等. 帕金森病血钙水平与认知功能相关性分析[J]. 中华医学杂志, 2016, 96(41):3284-3288. [13] Mehrpooya M, Larti F, Nozari Y, et al. Study of serum uric acid levels in myocardial infarction and its association with killip class[J]. Acta Med Iran, 2017, 55(2):97-102. [14] George AK, Behera J, Kelly KE, et al. Exercise mitigates alcohol induced endoplasmic reticulum stress mediated cognitive impairment through ATF6-Herp signaling[J]. Sci Rep, 2018, 8(1):5158. [15] 于群涛,孔敏,巴茂文, 等.帕金森病患者认知功能障碍与同型半胱氨酸的相关性研究[J].中华老年心脑血管病杂志,2018,20(6):631-634.